The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

Toxicology and Applied Pharmacology

Volumn 249, Issue 2, 2010, Pages 132-139

  Hasinoff, Brian B ^a   Patel, Daywin ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Anticancer; Cardiotoxicity; Inhibition; Kinase; Myocyte; Tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; CANERTINIB; DASATINIB; DOVITINIB; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; IMATINIB; LAPATINIB; MIDOSTAURIN; MOTESANIB; PAZOPANIB; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STAUROSPORINE; SUNITINIB; TANDUTINIB; TOZASERTIB; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME INHIBITION; HEART MUSCLE CELL; HEART MUSCLE INJURY; IN VITRO STUDY; NEWBORN; NONHUMAN; RAT;

ANIMALS; ANIMALS, NEWBORN; ANTINEOPLASTIC AGENTS; MYOCYTES, CARDIAC; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 77958194741     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.08.026     Document Type: Article

References (33)

1. Adderley S.R., Fitzgerald D.J. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J. Biol. Chem. 1999, 274:5038-5046.
2. Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J. Natl Cancer Inst. 2010, 102:14-25.
3. Bueno O.F., Molkentin J.D. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ. Res. 2002, 91:776-781.
4. Chen M.H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118:84-95.
5. Cheng H., Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ. Res. 2010, 106:21-34.
6. Chien A.J., Rugo H.S. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin. Drug Saf. 2010, 9:335-346.
7. Chintalgattu V., Patel S.S., Khakoo A.Y. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol. Oncol. Clin. North Am. 2009, 23:97-107.
8. Fabian M.A., Biggs W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lelias J.M., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., Lockhart D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23:329-336.
9. Force T., Kerkela R. Cardiotoxicity of the new cancer therapeutics-mechanisms of, and approaches to, the problem. Drug Discov. Today 2008, 13:778-784.
10. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 2007, 7:332-344.
11. Ghoreschi K., Laurence A., O'Shea J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nat. Immunol. 2009, 10:356-360.
12. Guilluy C., Rolli-Derkinderen M., Loufrani L., Bourge A., Henrion D., Sabourin L., Loirand G., Pacaud P. Ste20-related kinase SLK phosphorylates Ser188 of RhoA to induce vasodilation in response to angiotensin II Type 2 receptor activation. Circ. Res. 2008, 102:1265-1274.
13. Hasinoff B.B. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol. Appl. Pharmacol. 2010, 244:190-195.
14. Hasinoff B.B., Patel D. Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovasc. Toxicol. 2010, 10:1-8.
15. Hasinoff B.B., Patel D., O'Hara K.A. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol. Pharmacol. 2008, 74:1722-1728.
16. Hershko C., Link G., Tzahor M., Kaltwasser J.P., Athias P., Grynberg A., Pinson A. Anthracycline cytotoxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J. Lab. Clin. Med. 1993, 122:245-251.
17. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., Faraoni R., Floyd M., Hunt J.P., Lockhart D.J., Milanov Z.V., Morrison M.J., Pallares G., Patel H.K., Pritchard S., Wodicka L.M., Zarrinkar P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
18. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F.J., Rosenzweig A., Salomon R.N., Van Etten R.A., Alroy J., Durand J.B., Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006, 12:908-916.
19. Kerkela R., Woulfe K.C., Durand J.B., Vagnozzi R., Kramer D., Chu T.F., Beahm C., Chen M.H., Force T. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2009, 2:15-25.
20. Lepilina A., Coon A.N., Kikuchi K., Holdway J.E., Roberts R.W., Burns C.G., Poss K.D. A dynamic epicardial injury response supports progenitor cell activity during zebrafish heart regeneration. Cell 2006, 127:607-619.
21. Menna P., Salvatorelli E., Minotti G. Cardiotoxicity of antitumor drugs. Chem. Res. Toxicol. 2008, 21:978-989.
22. Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem. 2010, 53:1413-1437.
23. Mosse Y.P., Wood A., Maris J.M. Inhibition of ALK signaling for cancer therapy. Clin. Cancer Res. 2009, 15:5609-5614.
24. Pentassuglia L., Graf M., Lane H., Kuramochi Y., Cote G., Timolati F., Sawyer D.B., Zuppinger C., Suter T.M. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp. Cell Res. 2009, 315:1302-1312.
25. Perez E.A., Koehler M., Byrne J., Preston A.J., Rappold E., Ewer M.S. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 2008, 83:679-686.
26. Schroeder P.E., Patel D., Hasinoff B.B. The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites. Drug Metab. Dispos. 2008, 36:1780-1785.
27. Storbeck C.J., Daniel K., Zhang Y.H., Lunde J., Scime A., Asakura A., Jasmin B., Korneluk R.G., Sabourin L.A. Ste20-like kinase SLK displays myofiber type specificity and is involved in C2C12 myoblast differentiation. Muscle Nerve 2004, 29:553-564.
28. Su A.I., Wiltshire T., Batalov S., Lapp H., Ching K.A., Block D., Zhang J., Soden R., Hayakawa M., Kreiman G., Cooke M.P., Walker J.R., Hogenesch J.B. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl Acad. Sci. USA 2004, 101:6062-6067.
29. Wolf A., Couttet P., Dong M., Grenet O., Heron M., Junker U., Laengle U., Ledieu D., Marrer E., Nussher A., Persohn E., Pognan F., Riviere G.J., Roth D.R., Trendelenburg C., Tsao J., Roman D. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk. Res. 2010, 34:1180-1188.
30. Yanai I., Benjamin H., Shmoish M., Chalifa-Caspi V., Shklar M., Ophir R., Bar-Even A., Horn-Saban S., Safran M., Domany E., Lancet D., Shmueli O. Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics 2005, 21:650-659.
31. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 2009, 53:2231-2247.
32. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9:28-39.
33. Zhao P., Caretti G., Mitchell S., McKeehan W.L., Boskey A.L., Pachman L.M., Sartorelli V., Hoffman E.P. Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J. Biol. Chem. 2006, 281:429-438.